{
    "General": {
        "Code": "5GV",
        "Type": "Common Stock",
        "Name": "GENOVIS AB SE-40",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "SE0002485979",
        "LEI": "549300T5KGFRYR7ZST20",
        "PrimaryTicker": "GENO.ST",
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "December",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Biotechnology",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Biotechnology",
        "GicSubIndustry": "Biotechnology",
        "Description": "Genovis AB (publ.) designs, develops, and sells tools for development of new treatment methods and diagnostics for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; GingisKHAN, a cysteine protease that digests human IgG1; and FabDELLO, a protease that digests human IgG1. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology for site-specific and quantitative conjugation of IgG; TransGLYCIT, a platform technology that enables site-specific human IgG glycan remodeling; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase hydrolyzing the amide bond between the polypeptide asparagine and the innermost GlcNAc; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a \u00df-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin for purification of mucin-type O-glycosylated proteins and peptides; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 38,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 312271392,
        "MarketCapitalizationMln": 312.2714,
        "EBITDA": null,
        "PERatio": 68.1429,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 0.044,
        "DividendShare": 0,
        "DividendYield": 0,
        "EarningsShare": 0.07,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2023-06-30",
        "ProfitMargin": 0.3783,
        "OperatingMarginTTM": 0,
        "ReturnOnAssetsTTM": 0.1815,
        "ReturnOnEquityTTM": 0.3621,
        "RevenueTTM": 0,
        "RevenuePerShareTTM": 0,
        "QuarterlyRevenueGrowthYOY": 0.397,
        "GrossProfitTTM": 88543498,
        "DilutedEpsTTM": 0.07,
        "QuarterlyEarningsGrowthYOY": 21.649
    },
    "Valuation": {
        "TrailingPE": 68.1429,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": 274301344,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 65465700,
        "SharesFloat": 55094636,
        "PercentInsiders": 18.556,
        "PercentInstitutions": 45.149,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 1.5859,
        "52WeekHigh": 6.38,
        "52WeekLow": 2.885,
        "50DayMA": 3.8881,
        "200DayMA": 4.5531,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0,
        "ForwardAnnualDividendYield": 0,
        "PayoutRatio": 0,
        "DividendDate": null,
        "ExDividendDate": null,
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {}
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}